The US Food and Drugs
Administration (FDA) has approved
Myalept (metreleptin for injection)
as replacement therapy for
complications of leptin deficiency
in patients with congenital
generalised or acquired generalised
lipodystrophy, a condition
associated with a lack of fat tissue.
Patients with generalised
lipodystrophy had low leptin levels,
the FDA said.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.